The Long Road to an Effective Vaccine for Meningococcus Group B (MenB)

Annals of Medicine and Surgery

Volumn 2, Issue 2, 2013, Pages 53-56

  Shea, Michael W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Evidence Based Medicine; Mass Media; Misrepresentation; Randomised Controlled Trials

Indexed keywords

EID: 84892662258     PISSN: 20490801     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2049-0801(13)70037-2     Document Type: Review

References (64)

1. Schwartz B., Moore P.S., Broome C.V. Global epidemiology of meningococcal disease. Clin Microbiol Rev 1989, 2(Suppl 29):S118-S124.
2. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl 2):B51-B63.
3. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus I. The role of humoral antibodies. J Exp Med 1969, 129(6):1307-1326.
4. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human Immunity to the Meningococcus II. Development of Natural Immunity. J Exp Med 1969, 129(6):1327-1348.
5. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine 2005, 23(17-18):2222-2227.
6. Fijen C.A., Kuijper E.J., Te Bulte M.T., et al. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 1999, 28(1):98-105.
7. Campbell H., Andrews N., Borrow R., et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010, 17(5):840-847.
8. Siddique A., Buisine N., Chalmers R. The transposon-like Correia elements encode numerous strong promoters and provide a potential new mechanism for phase variation in the meningococcus. PLoS Genet 2011, 7(1):e1001277.
9. Bucci C., Lavitola A., Salvatore P., et al. Hypermutation in Pathogenic Bacteria: Frequent Phase Variation in Meningococci Is a Phenotypic Trait of a Specialized Mutator Biotype. Mol cell 1999, 3:435-445.
10. Tettelin H., Saunders N.J., Heidelberg J., et al. Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58. Science 2000, 287(5459):1809-1815.
11. Lucidarme J., Comanducci M., Findlow J., et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17(6):919-929.
12. Ladhani S.N., Flood J.S., Ramsay M.E., et al. Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines. Vaccine 2012, 30(24):3710-3716.
13. Poland G.A. Vaccines against Lyme disease: What happened and what lessons can we learn?. Clin Infect Dis 2011, 52(Suppl 3):s253-s258.
14. Stanek G., Wormser G.P., Gray J., et al. Lyme borreliosis. Lancet 2012, 379(9814):461-473.
15. Keyserling H., Papa T., Koranyi K., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005, 159(10):907-913.
16. ®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C W-135 and Y. Expert Rev Vaccines 2011, 10(1):21-33.
17. Maiden M.C.J., Ibarz-Pavó A.B., Urwin R., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197(5):737-743.
18. Ibarz-Pavó A.B., Maclennan J., Andrews N.J., et al. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis 2011, 204(7):1046-1053.
19. Auckland C., Gray S., Borrow R., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006, 194(12):1745-1752.
20. Kim S.H., Pezzoli L., Yacouba H., et al. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PloS one 2012, 7(1):e29116. Available from: ■■■.
21. Finne J., Bitter-Suermann D., Goridis C., et al. IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987, 138(12):4402-4407.
22. Devi S.J., Schneerson R., Egan W., et al. Identity between polysaccharide antigens of Moraxella nonliquefaciens, group B Neisseria meningitidis, and Escherichia coli K1 (non-O acetylated). Infect Immun 1991, 59(2):732-736.
23. Wyle F.A., Artenstein M.S., Brandt B.L., et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972, 126(5):514-521.
24. Devi S., Robbins J., Schneerson R. Antibodies to poly[(2-8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci U S A 1991, 88:7175-7179. August.
25. Leinonen M. Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay. Infect Immun 1982, 38(3):1203-1207.
26. Collins B.S. Gram-negative outer membrane vesicles in vaccine development. Discov Med 2011, 12(62):7-15.
27. Bjune G., Hoiby E., Gronnesby J., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338(8775):1093-1096.
28. Holst J., Martin D., Arnold R., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl 2):B3-B12.
29. Russell J.E., Jolley K.A., Feavers I.M., et al. PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004, 10(4):674-678.
30. Sorhouet Pereira C., Regueira M., Mollerach M. PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine. J Med Microbiol 2008, 57(Pt 3):338-342.
31. Martin D., Ruijne N., McCallum L. The VR2 epitope on the PorA P1 7-2, 4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006, 13(4):486-491.
32. Tappero J.W., Lagos R., Ballesteros A.M., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281(16):1520-1527.
33. Robbins J.B., Schneerson R., Xie G., et al. Capsular polysaccharide vaccine for Group B Neisseria meningitidis Escherichia coli K1, and Pasteurella haemolytica A2. Proc Natl Acad Sci U S A 2011, 108(44):17871-17875.
34. Gottfredsson M., Reynisson I.K., Ingvarsson R.F., et al. Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin Infect Dis 2011, 53(9):e117-e124.
35. Claassen I., Meylis J., Van der Ley P., et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996, 14(10):1001-1008.
36. Weynants V.E., Feron C.M., Goraj K.K., et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007, 75(11):5434-5442.
37. Bonvehí P., Boutriau D., Casellas J., et al. Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clin Vaccine Immunol 2010, 17(9):1460-1466.
38. Weynants V., Denoël P., Devos N., et al. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect Immun 2009, 77(5):2084-2093.
39. Zollinger W.D., Donets M.A., Schmiel D.H., et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 2010, 28(31):5057-5067.
40. Pinto V.B., Moran E.E., Cruz F., et al. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 2011, 29(44):7752-7758.
41. Pizza M., Scarlato V., Masignani V., et al. Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing. Science 2000, 287(5459):1816-1820.
42. Giuliani M.M., Adu-Bobie J., Comanducci M., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103(29):10834-10839.
43. Comanducci M., Bambini S., Brunelli B., et al. NadA, a Novel Vaccine Candidate of Neisseria meningitidis. J Exp Med 2002, 195(11):1445-1454.
44. Welsch J.A., Moe G.R., Rossi R., et al. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003, 188(11):1730-1740.
45. Serruto D., Spadafina T., Ciucchi L., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 2010, 107(8):3770-3775.
46. Masignani V., Comanducci M., Giuliani M.M., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197(6):789-799.
47. Madico G., Welsch J.A., Lewis L.A., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177(1):501-510.
48. Findlow J., Borrow R., Snape M.D., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51(10):1127-1137.
49. Gossger N., Snape M., Yu L., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307(6):573-582.
50. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379(9816):617-624.
51. Toneatto D., Oster P., deBoer C.W., et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin 2011, 7(7):781-791.
52. Beernink P.T., Welsch J.A., Harrison L.H., et al. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007, 195(10):1472-1479.
53. Novartis. V72P16. http://www.clinicaltrials.gov/.
54. Vesikari T., Esposito S., Prymula R., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381(9869):825-835.
55. Iacobucci G. First meningitis B vaccine could be available in UK next year. BMJ 2012, 345:e7867.
56. Snape M.D., Medini D., Halperin S.A., et al. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012, 30(Suppl 2):B67-B72.
57. Beernink P.T., Caugant D.A., Welsch J.A., et al. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A W-135, and X strains from Africa. J Infect Dis 2009, 199(9):1360-1368.
58. Hong E., Giuliani M.M., Deghmane A.-E., et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?. Vaccine 2012, 31(7):1113-1116.
59. Lucidarme J., Tan L., Exley R.M., et al. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccin Immunol 2011, 18(6):1002-1014.
60. Beernink P.T., Shaughnessy J., Pajon R., et al. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Path 2012, 8(5):e1002688.
61. Sadarangani M., Pollard A.J., Gray-Owen S.D. Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol Rev 2011, 35(3):498-514.
62. Fijen C.a, Kuijper E.J., Drogari-Apiranthitou M., et al. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1998, 114(3):362-369.
63. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(2):148-158.
64. Drabick J.J., Brandt B.L., Moran E.E., et al. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 1999, 18(1-2):160-172.